KEVIN R. SAYER - 08 Mar 2025 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
Chairman, CEO & President, Director
Signature
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Kevin R. Sayer
Issuer symbol
DXCM
Transactions as of
08 Mar 2025
Transactions value $
$0
Form type
4
Filing time
11 Mar 2025, 19:17:47 UTC
Previous filing
30 Jan 2025
Next filing
14 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Award $0 +85.5K +26.8% $0.00 405K 08 Mar 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2 Included in this number are 138,091 unvested restricted stock units, 85,490 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 34,461 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 18,140 of which were granted on March 9, 2023 and shall vest through March 8, 2026.